HCV infection and hemodialysis

Area of Science:

• Nephrology
• Hepatology
• Infectious Diseases

Background:

• Hepatitis C virus (HCV) infections are prevalent in hemodialysis patients, often linked to transfusions and nosocomial contamination.
• HCV infection can progress to cirrhosis in 10% of dialysis patients, complicating transplantation due to immunosuppressive therapy.

Purpose of the Study:

• To evaluate the histologic impact of HCV in hemodialysis patients.
• To discuss management strategies for HCV in dialysis patients, including transplantation considerations and treatment options.

Main Methods:

• Early liver biopsy for HCV-RNA positive hemodialysis patients to assess liver disease severity.
• Discussion of combined liver-kidney transplantation for dialysis patients with cirrhosis.
• Administration of standard alpha-interferon as the sole treatment for HCV in dialysis patients.

Main Results:

• Standard alpha-interferon achieves a 30% sustained viral eradication rate in dialysis patients.
• Alpha-interferon is indicated for acute hepatitis C, significant liver disease (fibrosis score ≥2), symptomatic cryoglobulinemia, and renal transplant candidates.
• Alpha-interferon is contraindicated in kidney recipients due to rejection risks.

Conclusions:

• Early liver biopsy and timely treatment decisions are crucial for HCV-positive hemodialysis patients.
• Combined liver-kidney transplantation should be considered for dialysis patients with cirrhosis.
• Preventive measures focus on universal hygiene due to the lack of an HCV vaccine and contraindications for certain treatments.